Xiao-Jie Xu (Xiaojie Xu)

Years Active: 2021-2023
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Zhijia Sun, Haixing Mai, Chunyuan Xue, Zhongyi Fan, Jiangbo Li, Hairui Chen, Nan Huo, Xiaofeng Kang, Chuanhao Tang, Liaoxin Fang, Hui Zhao, Yuchen Han, Chao Sun, Huanyan Peng, Yimeng Du, Jing Yang, Nan Du, Xiao-Jie Xu
Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination. Journal for immunotherapy of cancer 11 (12) (2023)
Zhongyi Fan, Jingjing Duan, Pu Luo, Ling Shao, Qiong Chen, Xiaohua Tan, Lei Zhang, Xiao-Jie Xu
SLC25A38 as a novel biomarker for metastasis and clinical outcome in uveal melanoma. Cell death & disease 13 (4) (2022)
Nan Huo, Rui Cong, Zhi-Jia Sun, Wen-Chao Li, Xiang Zhu, Chun-Yuan Xue, Zhao Chen, Lu-Yuan Ma, Zhong Chu, Yu-Chen Han, Xiao-Feng Kang, Song-Hao Jia, Nan Du, Lei Kang, Xiao-Jie Xu
STAT3/LINC00671 axis regulates papillary thyroid tumor growth and metastasis via LDHA-mediated glycolysis. Cell death & disease 12 (9) (2021)

Xiao-Jie Xu.css-eqlu8i{font-size:small;padding-left:4px;} (Xiaojie Xu)